These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 25044219)

  • 61. Pharmacokinetics of the Long-Acting Basal Insulin LY2605541 in Subjects With Varying Degrees of Renal Function.
    Linnebjerg H; Choi SL; Lam EC; Mace KF; Hodgson TS; Sinha VP
    Clin Pharmacol Drug Dev; 2016 May; 5(3):216-24. PubMed ID: 27163501
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pharmacokinetics of Enarodustat in Non-Japanese and Japanese Healthy Subjects and in Patients With End-Stage Renal Disease on Hemodialysis.
    Pai SM; Kambhampati SRP; Naruhashi S; Yamada H
    Clin Pharmacol Drug Dev; 2023 Jul; 12(7):683-690. PubMed ID: 37203396
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clearance of linezolid via continuous venovenous hemodiafiltration.
    Mauro LS; Peloquin CA; Schmude K; Assaly R; Malhotra D
    Am J Kidney Dis; 2006 Jun; 47(6):e83-6. PubMed ID: 16731287
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
    Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
    Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Impact of ontogeny on linezolid disposition in neonates and infants.
    Kearns GL; Jungbluth GL; Abdel-Rahman SM; Hopkins NK; Welshman IR; Grzebyk RP; Bruss JB; Van Den Anker JN;
    Clin Pharmacol Ther; 2003 Nov; 74(5):413-22. PubMed ID: 14586382
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Comparison of Levetiracetam Dosing Regimens in End-Stage Renal Disease Patients Undergoing Intermittent Hemodialysis.
    Shiue HJ; Taylor M; Sands KA
    Ann Pharmacother; 2017 Oct; 51(10):862-865. PubMed ID: 28582998
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Minor impairment of oral iron absorption in non-diabetic new dialysis patients.
    Tovbin D; Schnaider A; Vorobiov M; Rogachev B; Basok A; Shull P; Novack V; Friger M; Avramov D; Zlotnik M
    J Nephrol; 2005; 18(2):174-80. PubMed ID: 15931645
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Single dose pharmacokinetics of linezolid in infants and children.
    Kearns GL; Abdel-Rahman SM; Blumer JL; Reed MD; James LP; Jacobs RF; Bradley JA; Welshman IR; Jungbluth GL; Stalker DJ;
    Pediatr Infect Dis J; 2000 Dec; 19(12):1178-84. PubMed ID: 11144380
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Risk factors for linezolid-associated thrombocytopenia in adult patients.
    Natsumoto B; Yokota K; Omata F; Furukawa K
    Infection; 2014 Dec; 42(6):1007-12. PubMed ID: 25119433
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis.
    Wang X; Tirucherai G; Marbury TC; Wang J; Chang M; Zhang D; Song Y; Pursley J; Boyd RA; Frost C
    J Clin Pharmacol; 2016 May; 56(5):628-36. PubMed ID: 26331581
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects.
    O'Donnell J; Preston RA; Mamikonyan G; Stone E; Isaacs R
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31307978
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic Hemodialysis.
    Dias C; Moore KT; Murphy J; Ariyawansa J; Smith W; Mills RM; Weir MR
    Am J Nephrol; 2016; 43(4):229-36. PubMed ID: 27100875
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pharmacokinetics of serelaxin in patients with severe renal impairment or end-stage renal disease requiring hemodialysis: A single-dose, open-label, parallel-group study.
    Dahlke M; Halabi A; Canadi J; Tsubouchi C; Machineni S; Pang Y
    J Clin Pharmacol; 2016 Apr; 56(4):474-83. PubMed ID: 26239266
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Single-dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment.
    Marbury T; Lawitz E; Stonerock R; Gonzalez M; Jiao J; Breeding J; Haqq C; Verboven P; Stieltjes H; Yu M; Molina A; Acharya M; Chien C; Tran N
    J Clin Pharmacol; 2014 Jul; 54(7):732-41. PubMed ID: 24374856
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pharmacokinetics, Dialysability, and Safety of Gadopiclenol, a New Gadolinium-Based Contrast Agent, in Patients With Impaired Renal Function.
    Bradu A; Penescu M; Pitrou C; Hao J; Bourrinet P
    Invest Radiol; 2021 Aug; 56(8):486-493. PubMed ID: 34197356
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effect of hemodialysis on platelet function in end-stage renal disease Egyptian patients using in vitro closure time test (PFA-100 analyzer).
    Mekawy MA; Habashy DM; Abd El-Mohsen WA
    Platelets; 2015; 26(5):443-7. PubMed ID: 24955720
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pharmacokinetics of linezolid during continuous hemodiafiltration: A case report.
    Yamashina T; Tsuruyama M; Odawara M; Tsuruta M; Miyata H; Kozono A; Tsuji Y; Miyoshi T; Kawamata Y; Hiraki Y
    J Infect Chemother; 2017 Oct; 23(10):709-712. PubMed ID: 28408302
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End-Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects.
    Dymond AW; Martin P; So K; Huang Y; Severin P; Holmes V; Mariani G; Marbury T
    J Clin Pharmacol; 2017 May; 57(5):592-605. PubMed ID: 28019010
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis.
    Buerger C; Plock N; Dehghanyar P; Joukhadar C; Kloft C
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2455-63. PubMed ID: 16801426
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Filtration of Macrophage Migration Inhibitory Factor (MIF) in Patients with End Stage Renal Disease Undergoing Hemodialysis.
    Luedike P; Rammos C; Pohl J; Heisler M; Totzeck M; Kleophas W; Hetzel GR; Kelm M; Hendgen-Cotta U; Rassaf T
    PLoS One; 2015; 10(10):e0140215. PubMed ID: 26485680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.